Earnings calls

P I Industries concall ledger

Every earnings call for PIIND — management tone, guidance, KPIs and promise tracking, quarter by quarter.

PIIND · 5 transcripts · Chemicals · latest Q4 FY26

Q4 FY26Published 20 May 2026Call held 20 May 2026

PIIND Q4 FY26 Earnings Call Transcript & Analysis

Gross Margin58%

Gross Margin 58%. Full year FY26 consolidated revenue of ₹67,137 million with healthy EBITDA margins of 25%.

Read full transcript & analysis

Q3 FY26Published 13 Feb 2026Call held 13 Feb 2026

PIIND Q3 FY26 Earnings Call Transcript & Analysis

Revenue₹1,375.7 crEBITDA Margin27%Gross Margin59%

Revenue ₹1,376 cr; EBITDA Margin (9M) 27.0%; Gross Margin 59.0%. Pharma business delivered 50% year-on-year growth over nine months.

Read full transcript & analysis

Q2 FY26Published 12 Nov 2025Call held 12 Nov 2025

PIIND Q2 FY26 Earnings Call Transcript & Analysis

Revenue18,723 million−16% YoY

Revenue 18723 million (−16% YoY). Revenue declined 16% YoY to ₹18,723 million in Q2 FY26.

Read full transcript & analysis

Q1 FY26Published 13 Aug 2025Call held 13 Aug 2025

PIIND Q1 FY26 Earnings Call Transcript & Analysis

Revenue19,005 million−8% YoYEBITDA Margin27.5%Gross Margin57.4%

Revenue 19005 million (−8% YoY); EBITDA Margin 27.5%; Gross Margin 57.4%. Pharma business revenue grew 186% YoY.

Read full transcript & analysis

Q4 FY25Published 20 May 2025Call held 20 May 2025

PIIND Q4 FY25 Earnings Call Transcript & Analysis

Revenue₹1,787.1 cr+3% YoYEBITDA—+3% YoYEBITDA Margin25.6%PAT₹1,660.2 cr−1% YoY

Revenue ₹1,787 cr (+3% YoY); EBITDA Margin 25.6%. Q4 FY25 revenue grew 3% YoY to ₹1,787.1 crores, with full year FY25 revenue up 4% to ₹7,977.8 crores.

Read full transcript & analysis